Skip to Content

Kionex Side Effects

Generic name: sodium polystyrene sulfonate

Medically reviewed by Drugs.com. Last updated on Nov 21, 2020.

Note: This document contains side effect information about sodium polystyrene sulfonate. Some of the dosage forms listed on this page may not apply to the brand name Kionex.

For the Consumer

Applies to sodium polystyrene sulfonate: oral or rectal powder for suspension, oral or rectal suspension

Side effects include:

Gastric irritation, anorexia, constipation, diarrhea, fecal impaction, GI concretions (bezoars), nausea, vomiting, hypokalemia, hypocalcemia, hypomagnesemia, clinically important sodium retention.

For Healthcare Professionals

Applies to sodium polystyrene sulfonate: oral suspension, oral and rectal powder, oral and rectal suspension, rectal enema

Gastrointestinal

Rare (0.01% to 0.1%): Intestinal/colonic necrosis

Frequency not reported: Gastric irritation, nausea, vomiting, constipation, diarrhea, fecal impaction, intestinal obstruction, other serious gastrointestinal (GI) adverse reactions

Postmarketing reports: GI concretions/bezoars, ischemic colitis, GI tract ulceration, intestinal perforation, GI stenosis[Ref]

Nausea, vomiting, and constipation have occurred, especially with high doses. In clinical trials, fecal impaction occurred in geriatric patients given large doses; children have experienced impaction with rectal administration. Following oral administration, intestinal obstruction with aluminum hydroxide concretions and bezoar formation occurred in neonates. In postmarketing reports, gastrointestinal tract ulcerations, necrosis, and ischemic colitis may have resulted in intestinal perforation.[Ref]

Metabolic

Frequency not reported: Anorexia, hypokalemia, hypocalcemia, hypomagnesemia, significant sodium retention[Ref]

Nervous system

Postmarketing reports: Grand mal seizure[Ref]

A grand mal seizure occurred in 1 patient with renal dysfunction and concomitant use of this drug and magnesium hydroxide.[Ref]

Respiratory

Postmarketing reports: Acute bronchitis, bronchopneumonia[Ref]

Bronchitis with/without pneumonia occurred after inhalation of particles of this drug.[Ref]

References

1. "Product Information. Kayexalate (sodium polystyrene sulfonate)." Sanofi Winthrop Pharmaceuticals, New York, NY.

2. Cerner Multum, Inc. "Australian Product Information." O 0

3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.